Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
News|Articles|January 17, 2025
Key Drugs to Watch in Oncology, Hematology, and Neurology for 2025
Author(s)Luke Halpern, Associate Editor
These drugs are set to revolutionize their respective disease states in 2025.
Advertisement
Advertisement
Each year, dozens of new drugs are launched and enter the market, offering countless patients new therapeutic options for a multitude of common diseases and conditions, such as in hemophilia management, oncology, or treatment of neurological conditions. In 2025, multiple drugs are poised to significantly transform their indicated disease states in the coming year and beyond.1
Related to this article
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
Advertisement
Advertisement